Product Information
DROXIDOPA 300 MG CAPSULE is a generic product labeled by Slate Run Pharmaceuticals LLC, priced at $2.2477 per EA under NDC 70436014206. Its NADAC has been published 100 times since Jun 21, 2023.
FDA first approved this application on Nov 1, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/1
Manufacturer
Slate Run Pharmaceuticals LLCNDC
70436014206
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
4/23/2025
Active Ingredients
DROXIDOPAApproval Type
Generic (ANDA)
FDA Application
ANDA215265FDA Approved
11/1/2021
TE Code
AB
On Market Since
11/10/2021
Pharmacological Classes
Price Statistics
The NADAC for DROXIDOPA 300 MG CAPSULE has been published 100 times since Jun 21, 2023, and over the history we have for it it has declined 12.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.2477 per EA |
|---|---|
| All-time high | $3.0478 (Nov 13, 2024) |
| All-time low | $2.2477 (Apr 23, 2025) |
| Median price | $2.5551 |
| Average price | $2.6407 |
| Largest weekly change | +12.0% (Aug 21, 2024) |
| Weeks tracked | 100 |
| Tracking since | Jun 21, 2023 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
-12.0%
5Y
N/A
All
-12.0%
Last surveyed May 14, 2025 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 5% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of DROXIDOPA 300 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for DROXIDOPA 300 MG CAPSULE, manufactured by Slate Run Pharmaceuticals LLC, is $2.2477 per EA (NDC 70436014206), effective May 14, 2025.
How has the price of DROXIDOPA 300 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for DROXIDOPA 300 MG CAPSULE has declined 12.0%. It has been tracked across 100 weekly CMS publications since Jun 21, 2023.
What are the highest and lowest recorded NADAC prices for DROXIDOPA 300 MG CAPSULE?
Since Jun 21, 2023, the NADAC for DROXIDOPA 300 MG CAPSULE has ranged from a low of $2.2477 (Apr 23, 2025) to a high of $3.0478 (Nov 13, 2024), with a median of $2.5551 per EA.
Are there cheaper alternatives to DROXIDOPA 300 MG CAPSULE?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, DROXIDOPA 300 MG CAPSULE, is $2.1456 per EA — about 5% below DROXIDOPA 300 MG CAPSULE.
Who manufactures DROXIDOPA 300 MG CAPSULE?
DROXIDOPA 300 MG CAPSULE (NDC 70436014206) is labeled by Slate Run Pharmaceuticals LLC, and CMS classifies it as a generic product.